triocean | Adobe Stock
The U.S. Food & Drug Administration (FDA) approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
Palforzia has been approved since January 2020 for initiation of treatment in individuals ages 4 through 17 years with a confirmed diagnosis of peanut allergy with up-dosing and maintenance in individuals 4 years of age and older.
Those who take Palforzia must continue to avoid peanuts in their diets. A Risk Evaluation and Mitigation Strategy (REMS) is in place for Palforzia to mitigate the risk of anaphylaxis associated with Palforzia, which includes elements to assure safe use.
Latest from Quality Assurance & Food Safety
- IDFA Presents Leadership Award to Six Federal Officials at Annual Celebration of Dairy Reception
- Seeding The Future Global Food System Challenge is Changing Lives: Winners Reflections
- Raw Farm Products Recalled Following Bird Flu Virus Detections
- FDA Issues 2024 Voluntary National Retail Food Regulatory Program Standards
- GSA Launches Assurances Platform, Prism and Webinar Series in Partnership with Wholechain
- Multistate E. coli Outbreak Linked to Iceberg and Romaine Lettuce Blend
- FDA, USDA Seek Information About Food Date Labeling
- William Marler, Food Safety Advocate and Lawyer, Condemns Lack of Safety of U.S. Food Supply
